Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

IRIX 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Investor Conference Call
Full Press ReleaseSEC FilingsOur IRIX Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
  • 01.13.2025 - Patrick Mercer
  • 12.18.2024 - Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

Recent Filings

  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.14.2025 - 8-K Current report

MOUNTAIN VIEW, Calif.,Nov. 04, 2024(GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading onTuesday, November 12, 2024.

The Company’s management team will host a corresponding conference call beginning at2:00 p.m. PT/5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for international callers, using conference ID: 3650755. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website atwww.iridex.com.

AboutIridex Corporation

Iridex Corporationis a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietaryMicroPulse®technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases.Iridexproducts are sold inthe United Statesthrough a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit theIridexwebsite atwww.iridex.com.

MicroPulse®is a registered trademark ofIridex Corporation, Inc.inthe United States,Europeand other jurisdictions. © 2024Iridex Corporation. All rights reserved.

Investor Relations Contact:Philip TaylorGilmartin Groupinvestors@iridex.com

Primary Logo

Source: IRIDEX Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com